系统性炎症指标在卵巢癌中的研究进展
Research Advances in Systemic Inflammatory Indicators in Ovarian Cancer
DOI: 10.12677/jcpm.2025.42250, PDF,   
作者: 张晓露*, 刘芯瑜：延安大学医学院，陕西 延安；李红霞#：延安大学附属医院妇科，陕西 延安
关键词: 卵巢癌；炎症指标；系统性免疫炎症指数；Ovarian Cancer； Inflammatory Indicators； Systemic Immune-Inflammation Index
摘要: 系统性炎症指标作为一类简便易得的生物标志物，在卵巢癌的诊断、预后评估和治疗中展现出重要价值。本文综述了近年来淋巴细胞与单核细胞比值(LMR)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、系统性炎症反应指数(SIRI)、纤维蛋白原与白蛋白比值(FAR)以及系统性免疫炎症指数(SII)在卵巢癌中的研究进展。这些指标不仅与卵巢癌的分期、化疗反应和预后密切相关，还可作为卵巢癌辅助诊断的重要参考。然而，这些指标在临床应用中仍面临临界值不统一、特异性有限、缺乏前瞻性研究验证等问题。未来需要探索这些指标的生物学机制，建立标准化评估体系，并研究其在卵巢癌个体化治疗中的应用价值，以提高卵巢癌患者的生存率和生活质量。
Abstract: Systemic inflammatory indicators, as a category of readily accessible biomarkers, have demonstrated significant value in the diagnosis, prognostic evaluation, and treatment for ovarian cancer. This review summarizes recent advances in the study of lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic inflammatory response index (SIRI), fibrinogen-to-albumin ratio (FAR), and systemic immune-inflammation index (SII) in ovarian cancer. These indicators are not only closely associated with tumor staging, chemotherapy response, and prognosis but also serve as valuable adjuncts for auxiliary diagnosis. However, challenges remain in their clinical application, including inconsistent cutoff values, limited specificity, and a paucity of validation through prospective studies. Future research should focus on elucidating the biological mechanisms underlying these indicators, establishing standardized evaluation protocols, and exploring their potential in personalized treatment strategies to improve survival rates and quality of life for ovarian cancer patients.
文章引用：张晓露, 刘芯瑜, 李红霞. 系统性炎症指标在卵巢癌中的研究进展[J]. 临床个性化医学, 2025, 4(2): 835-842. https://doi.org/10.12677/jcpm.2025.42250

参考文献

[1] Tang, Z., Wang, Y., Wan, Y., Xie, Y., Li, S., Tao, D., et al. (2021) Apurinic/Apyrimidinic Endonuclease 1/Reduction-Oxidation Effector Factor-1 (APE1) Regulates the Expression of NLR Family Pyrin Domain Containing 3 (NLRP3) Inflammasome through Modulating Transcription Factor NF-κB and Promoting the Secretion of Inflammatory Mediators in Macrophages. Annals of Translational Medicine, 9, 145-145. [Google Scholar] [CrossRef] [PubMed]
[2] Keskin, S. and Altin, D. (2021) Predictor Role of Systemic Inflammation in Ovarian Cancer. Middle Black Sea Journal of Health Science, 7, 282-288. [Google Scholar] [CrossRef] 
[3] Dinca, A. (2024) Systemic Inflammatory Markers—Prognostic Value in Ovarian Cancer. Acta Endocrinologica (Bucharest), 20, 162-169. [Google Scholar] [CrossRef] [PubMed]
[4] Santiago, A.E., Paula, S.O.C.D., Carvalho, A.T.D., Cândido, E.B., Furtado, R.D.S. and Silva Filho, A.L.D. (2023) Systemic Inflammatory Patterns in Ovarian Cancer Patients: Analysis of Cytokines, Chemokines, and Microparticles. Revista Brasileira de Ginecologia e Obstetrícia/RBGO Gynecology and Obstetrics, 45, e780-e789. [Google Scholar] [CrossRef] [PubMed]
[5] Tang, Y., Hu, H., Tang, F., Lin, D., Shen, R., Deng, L., et al. (2020) Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer. Journal of Cancer, 11, 3165-3171. [Google Scholar] [CrossRef] [PubMed]
[6] Gong, J., Jiang, H., Shu, C., Hu, M., Huang, Y., Liu, Q., et al. (2019) Prognostic Value of Lymphocyte-to-Monocyte Ratio in Ovarian Cancer: A Meta-Analysis. Journal of Ovarian Research, 12, Article No. 51. [Google Scholar] [CrossRef] [PubMed]
[7] Lu, C., Zhou, L., Ouyang, J. and Yang, H. (2019) Prognostic Value of Lymphocyte-To-Monocyte Ratio in Ovarian Cancer. Medicine, 98, e15876. [Google Scholar] [CrossRef] [PubMed]
[8] Song, Q., Xu, S., Wu, J., Ling, L., Wang, S., Shu, X., et al. (2023) The Preoperative Platelet to Neutrophil Ratio and Lymphocyte to Monocyte Ratio Are Superior Prognostic Indicators Compared with Other Inflammatory Biomarkers in Ovarian Cancer. Frontiers in Immunology, 14, Article 1177403. [Google Scholar] [CrossRef] [PubMed]
[9] Jeong, M.J., Yoon, Y.N., Kang, Y.K., Kim, C.J., Nam, H.S. and Lee, Y.S. (2023) A Novel Score Using Lymphocyte-To-Monocyte Ratio in Blood and Malignant Body Fluid for Predicting Prognosis of Patients with Advanced Ovarian Cancer. Cancers, 15, Article 2328. [Google Scholar] [CrossRef] [PubMed]
[10] Akyol, D. and Özcan, F.G. (2025) The Effect of Preoperative Laboratory Values on Prognostic Factors Following Cytoreduction Surgery in Ovarian Cancer: Neutrophil Lymphocyte Ratio, Platelet Lymphocyte Ratio, and Lymphocyte Monocyte Ratio. Medicine, 104, e41504. [Google Scholar] [CrossRef] [PubMed]
[11] 张宁娟, 王东芳, 白利平. 血清指标CA125, VEGF, 全血NLR, MPV/PLT与卵巢癌患者预后的相关性分析[J]. 宁夏医学杂志, 2024, 46(5): 408-412.
[12] Huang , Q., Zhou, L., Zeng, W., Ma, Q., Wang, W., Zhong, M., et al. (2017) Prognostic Significance of Neutrophil-To-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cellular Physiology and Biochemistry, 41, 2411-2418. [Google Scholar] [CrossRef] [PubMed]
[13] Zhao, Z., Zhao, X., Lu, J., Xue, J., Liu, P. and Mao, H. (2018) Prognostic Roles of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Ovarian Cancer: A Meta-Analysis of Retrospective Studies. Archives of Gynecology and Obstetrics, 297, 849-857. [Google Scholar] [CrossRef] [PubMed]
[14] Miao, Y., Yan, Q., Li, S., Li, B. and Feng, Y. (2016) Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Are Predictive of Chemotherapeutic Response and Prognosis in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Cancer Biomarkers, 17, 33-40. [Google Scholar] [CrossRef] [PubMed]
[15] Liontos, M., Andrikopoulou, A., Koutsoukos, K., Markellos, C., Skafida, E., Fiste, O., et al. (2021) Neutrophil-to-Lymphocyte Ratio and Chemotherapy Response Score as Prognostic Markers in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy. Journal of Ovarian Research, 14, Article No. 148. [Google Scholar] [CrossRef] [PubMed]
[16] Winata, I.G., Pradnyana, I.W.A.S., Yusrika, M., Pradnyaandara, I.G.B.M.A. and Pradnyadevi, P.A.S. (2024) Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as an Early Prognostic Marker in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis. Asian Pacific Journal of Cancer Prevention, 25, 1921-1927. [Google Scholar] [CrossRef] [PubMed]
[17] Ma, X., Sun, X., Yang, G., Yu, M., Zhang, G., Yu, J., et al. (2017) The Platelet-to-Lymphocyte Ratio as a Predictor of Patient Outcomes in Ovarian Cancer: A Meta-Analysis. Climacteric, 20, 448-455. [Google Scholar] [CrossRef] [PubMed]
[18] Zhang, W., Liu, K., Hu, G. and Liang, W. (2015) Preoperative Platelet/Lymphocyte Ratio Is a Superior Prognostic Factor Compared to Other Systemic Inflammatory Response Markers in Ovarian Cancer Patients. Tumor Biology, 36, 8831-8837. [Google Scholar] [CrossRef] [PubMed]
[19] Bizon, M., Olszewski, M., Krason, B., Kochanowicz, E., Safiejko, K., Borowka, A., et al. (2025) The Diagnostic Role of the Platelet-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 26, Article 1841. [Google Scholar] [CrossRef] [PubMed]
[20] Prodromidou, A., Andreakos, P., Kazakos, C., Vlachos, D.E., Perrea, D. and Pergialiotis, V. (2017) The Diagnostic Efficacy of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer. Inflammation Research, 66, 467-475. [Google Scholar] [CrossRef] [PubMed]
[21] Mao, H. and Yang, F. (2023) Prognostic Significance of Systemic Immune-Inflammation Index in Patients with Ovarian Cancer: A Meta-Analysis. Frontiers in Oncology, 13, Article 1193962. [Google Scholar] [CrossRef] [PubMed]
[22] Chu, B., Chen, Y. and Pan, J. (2025) Prognostic Significance of Systemic Immune Inflammation Index for Ovarian Cancer: An Updated Systematic Review and Meta-Analysis. Journal of Ovarian Research, 18, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[23] Feng, J. and Wang, Q. (2023) Correlation of Systemic Immune-Inflammatory Response Index with Clinical Data in Patients with Malignant Ovarian Tumor. American Journal of Translational Research, 15, 3309-3317.
[24] Wang, J., Yin, S. and Chen, K. (2022) Predictive Value of the Systemic Immune-Inflammation Index for the Efficacy of Neoadjuvant Chemotherapy and Prognosis in Patients with Stage III Ovarian Cancer—A Retrospective Cohort Study. Gland Surgery, 11, 1639-1646. [Google Scholar] [CrossRef] [PubMed]
[25] Chen, W., Shan, B., Zhou, S., Yang, H. and Ye, S. (2022) Fibrinogen/Albumin Ratio as a Promising Predictor of Platinum Response and Survival in Ovarian Clear Cell Carcinoma. BMC Cancer, 22, Article No. 92. [Google Scholar] [CrossRef] [PubMed]
[26] Yu, W., Ye, Z., Fang, X., Jiang, X. and Jiang, Y. (2019) Preoperative Albumin-to-Fibrinogen Ratio Predicts Chemotherapy Resistance and Prognosis in Patients with Advanced Epithelial Ovarian Cancer. Journal of Ovarian Research, 12, Article No. 88. [Google Scholar] [CrossRef] [PubMed]
[27] Postl, M., Danisch, M., Schrott, F., Kofler, P., Petrov, P., Aust, S., et al. (2024) The Predictive Value of the Fibrinogen-Albumin-Ratio Index on Surgical Outcomes in Patients with Advanced High-Grade Serous Ovarian Cancer. Cancers, 16, Article 3295. [Google Scholar] [CrossRef] [PubMed]
[28] Song, L., Qi, J., Zhao, J., et al. (2023) Diagnostic Value of CA125, HE4, Systemic Immune-Inflammatory Index (SII), Fibrinogen-to-Albumin Ratio (FAR), and Prognostic Nutritional Index (PNI) in the Preoperative Investigation of Ovarian Masses. Medicine, 102, e35240.
[29] Nie, D., Gong, H., Mao, X. and Li, Z. (2019) Systemic Immune-Inflammation Index Predicts Prognosis in Patients with Epithelial Ovarian Cancer: A Retrospective Study. Gynecologic Oncology, 152, 259-264. [Google Scholar] [CrossRef] [PubMed]
[30] Okunade, K.S., John-Olabode, S.O., Soibi-Harry, A.P., Okoro, A.C., Adejimi, A.A., Ademuyiwa, I.Y., et al. (2023) Prognostic Performance of Pretreatment Systemic Immune-Inflammation Index in Women with Epithelial Ovarian Cancer. Future Science OA, 9, FSO897. [Google Scholar] [CrossRef] [PubMed]
[31] Fu, Y., Lin, H., Ou, Y., Wu, C. and Fu, H. (2024) Bevacizumab as a Mitigating Factor for the Impact of High Systemic Immune-Inflammation Index on Chemorefractory in Advanced Epithelial Ovarian Cancer. BMC Cancer, 24, Article No. 1377. [Google Scholar] [CrossRef] [PubMed]
[32] Song, L., Wu, Q., Bai, S., Zhao, J., Qi, J. and Zhang, J. (2024) Comparison of the Diagnostic Efficacy of Systemic Inflammatory Indicators in the Early Diagnosis of Ovarian Cancer. Frontiers in Oncology, 14, Article 1381268. [Google Scholar] [CrossRef] [PubMed]